awmsg logo



conestat alfa (Ruconest®)


Reference No. 786

Publication date:
06/11/2018


Appraisal information

conestat alfa (Ruconest®) 2100 units powder for solution for injection
conestat alfa (Ruconest®) 2100 units powder and solvent for solution for injection


Company: Pharming Group NV
BNF category: Respiratory system
NMG meeting date: 05/09/2018
AWMSG meeting date: 17/10/2018
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1718
Ratification by Welsh Government: 02/11/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Conestat alfa (Ruconest®) is recommended as an option for use within NHS Wales for the treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema due to C1 esterase inhibitor deficiency. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download